Antaros Medical
Antaros Medical, a leading innovator in the field of medical technology, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2012, the company has established itself within the pharmaceutical and biotechnology industries, focusing on advanced imaging solutions and drug development services. Antaros Medical is renowned for its unique expertise in non-invasive imaging techniques, particularly in the realm of pharmacokinetics and pharmacodynamics. Their core offerings include innovative imaging services that enhance drug development processes, setting them apart in a competitive market. With a commitment to advancing healthcare, Antaros Medical has achieved significant milestones, including collaborations with major pharmaceutical companies and contributions to pivotal clinical studies. Their position as a trusted partner in the medical research community underscores their dedication to improving patient outcomes through cutting-edge technology.
DitchCarbon Score
How does Antaros Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antaros Medical's score of 9 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Antaros Medical's reported carbon emissions
Antaros Medical, headquartered in Sweden, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2022 as the baseline year. This target has been validated through a streamlined process for small and medium-sized enterprises (SMEs) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its Scope 1 and Scope 2 commitments, Antaros Medical is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These initiatives reflect the company's dedication to sustainability and its proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antaros Medical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
